Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideABTAbbott Laboratories
FinDog View：Neutral
| Metric | ABT | AMGN |
|---|
| Close | 106.20 | 466.01 |
| Market Cap | $184B | $254B |
| 1M | +7.46% | +10.56% |
| P/E (TTM) | 39.1 | 28.5 |
| Forward P/E | 17.6 | 17.1 |
| P/E 5-Yr Percentile | 99 | 68 |
| P/S | 3.8 | 6.5 |
| P/B | 3.6 | 21.3 |
| Dividend Yield | 1.98% | 3.21% |
| Latest Quarter Revenue | $11.2B | $10.1B |
| Revenue YoY | +7.8% | +9.5% |
| Gross Margin | 56.2% | 72.0% |
| Latest Quarter EPS | 0.61 | 4.37 |
| Avg Post-Earnings Move | ±1.6% | ±5.2% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | 2.71% | 2.08% |
| 90-Day Net Insider Buying | −$46.9M | −$4.1M |
ABT · Revenue, Last 8 Quarters ($B)
AMGN · Revenue, Last 8 Quarters ($B)
